Which of the following is given to treat thrombocytopenia secondary to anti-cancer therapy and is known to stimulate progenitor megakaryocytes?
**Core Concept**
Thrombocytopenia secondary to anti-cancer therapy is a common side effect of chemotherapy and radiation. It occurs when the bone marrow is suppressed, leading to a decrease in platelet production. To treat this condition, medications that stimulate the production of platelets are used.
**Why the Correct Answer is Right**
Eltrombopag is a thrombopoietin receptor agonist that stimulates the production of platelets by activating progenitor megakaryocytes. This leads to an increase in platelet count and helps to prevent bleeding complications in patients with thrombocytopenia secondary to anti-cancer therapy. Eltrombopag works by mimicking the action of thrombopoietin, which is a hormone that regulates platelet production.
**Why Each Wrong Option is Incorrect**
**Option A:** Filgrastim is a granulocyte colony-stimulating factor (G-CSF) that stimulates the production of neutrophils, not platelets. It is used to treat neutropenia, not thrombocytopenia.
**Option B:** Epoetin alfa is an erythropoietin that stimulates the production of red blood cells, not platelets. It is used to treat anemia, not thrombocytopenia.
**Option C:** Darbepoetin alfa is a long-acting erythropoietin that stimulates the production of red blood cells, not platelets. It is used to treat anemia, not thrombocytopenia.
**Clinical Pearl / High-Yield Fact**
It's essential to note that thrombopoietin receptor agonists like eltrombopag are not a substitute for bone marrow recovery. Patients with thrombocytopenia secondary to anti-cancer therapy should be closely monitored for signs of bone marrow recovery, and eltrombopag should be used cautiously to avoid overstimulation of the bone marrow.
**Correct Answer:** A. Eltrombopag